Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report.

Mobocertinib 和贝伐单抗治疗 EGFR 外显子 20 插入突变的 Amivantamab 难治性肺癌 ： 1 例报告。

• 发表时间: 2023 Dec
• 来源期刊: JTO Clin Res Rep
• DOI: 10.1016/j.jtocrr.2023.100600
• PMID: 38124788
• 文章类型: Case Reports
• 作者列表: Kim J,Lee Y

关键词: Anti-angiogenesis; Case report; Drug resistance; EGFR exon 20 insertion; NSCLC; Targeted therapy

Abstract

Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.

摘要

Amivantamab是第一个在EGFR外显子20插入突变NSCLC中获得批准的药物。然而，在临床实践中，对amivantamab的原发性或继发性耐药性是一个常见问题。我们报告了一例EGFR外显子20突变的NSCLC患者，该患者对阿米伐他单抗具有原发性耐药性，但通过另一种EGFR外显子20插入特异性靶向药物莫博科替尼和贝伐单抗的联合治疗成功治疗。